The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials

Abstract Background Obesity prevalence has increased during the past few decades, causing a pandemic with an influx in other co-morbidities. Many factors influence weight gain in an obesogenic environment therefore strategies for treating obesity may vary from conventional dietary and physical activ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ranil Jayawardena, Tormalli V. Francis, Sachith Abhayaratna, Priyanga Ranasinghe
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Caralluma fimbriata Obesity Appetite Weight loss Slimluma Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/8e4d0cbfd05b49ca95df52e90d17045f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e4d0cbfd05b49ca95df52e90d17045f
record_format	dspace
spelling	oai:doaj.org-article:8e4d0cbfd05b49ca95df52e90d17045f2021-11-14T12:37:57ZThe use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials10.1186/s12906-021-03450-82662-7671https://doaj.org/article/8e4d0cbfd05b49ca95df52e90d17045f2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12906-021-03450-8https://doaj.org/toc/2662-7671Abstract Background Obesity prevalence has increased during the past few decades, causing a pandemic with an influx in other co-morbidities. Many factors influence weight gain in an obesogenic environment therefore strategies for treating obesity may vary from conventional dietary and physical activity interventions to pharamacotherapy. A shift in unconventional strategies as herbal products for treating obesity have been investigated and one such plant extract is Caralluma fimbriata (C. fimbriata). Further, the studies included were systematically reviewed to gather evidence on potential effects of C. fimbriata as an appetite suppressant and weight loss supplement. Methods A systematic review of clinical trials reporting the effects of C. fimbriata as appetite suppression and anti-obesity supplement was reported according to PRISMA guidelines. Data were obtained by searching three databases: PubMed®, Web of Science® and SciVerse Scopus® for studies published until 30th April 2020. Results A total of 7 articles studying C. fimbriata satisfied the inclusion and exclusion criteria and were sourced from various countries including Australia (3), Cuba (1), India (2) and Spain (1). Almost all studies recruited adults who were overweight or obese with a BMI > 25 kg/m2 (n = 5), with the exception of two studies, one that recruited healthy adults with a BMI average of 26.5 kg/m2 and the second one utilised a population of children and adolescents with Prader-Willis Syndrome (PWS). Parameters assessing obesity, biochemical and appetite factors were analysed by carrying out a meta-analysis. Compared to placebo controlled group, C. fimbriata extract significantly reduced WC by 1.59 cm (95% CI, − 3.07 to − 0.10, p = 0.041) and WHR by 0.06 (95% CI, − 0.12 to − 0.01, p = 0.05) although no significant effects were seen on BW, BMI and HC. Biochemical and appetite parameters outcome on C. fimbriata consumption had no significant changes. Any side effects of individuals who ingested the extract were reported by few studies of which most common effects were constipation, diarrhoea, nausea and rashes. Conclusion Appetite parameters showed no significant changes and metabolic parameters did not improve with C.fimbriata supplementation therefore it is unlikely to recommend C. fimbriata as a weight loss supplement and an appetite suppressant.Ranil JayawardenaTormalli V. FrancisSachith AbhayaratnaPriyanga RanasingheBMCarticleCaralluma fimbriataObesityAppetiteWeight lossSlimlumaOther systems of medicineRZ201-999ENBMC Complementary Medicine and Therapies, Vol 21, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Caralluma fimbriata Obesity Appetite Weight loss Slimluma Other systems of medicine RZ201-999
spellingShingle	Caralluma fimbriata Obesity Appetite Weight loss Slimluma Other systems of medicine RZ201-999 Ranil Jayawardena Tormalli V. Francis Sachith Abhayaratna Priyanga Ranasinghe The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
description	Abstract Background Obesity prevalence has increased during the past few decades, causing a pandemic with an influx in other co-morbidities. Many factors influence weight gain in an obesogenic environment therefore strategies for treating obesity may vary from conventional dietary and physical activity interventions to pharamacotherapy. A shift in unconventional strategies as herbal products for treating obesity have been investigated and one such plant extract is Caralluma fimbriata (C. fimbriata). Further, the studies included were systematically reviewed to gather evidence on potential effects of C. fimbriata as an appetite suppressant and weight loss supplement. Methods A systematic review of clinical trials reporting the effects of C. fimbriata as appetite suppression and anti-obesity supplement was reported according to PRISMA guidelines. Data were obtained by searching three databases: PubMed®, Web of Science® and SciVerse Scopus® for studies published until 30th April 2020. Results A total of 7 articles studying C. fimbriata satisfied the inclusion and exclusion criteria and were sourced from various countries including Australia (3), Cuba (1), India (2) and Spain (1). Almost all studies recruited adults who were overweight or obese with a BMI > 25 kg/m2 (n = 5), with the exception of two studies, one that recruited healthy adults with a BMI average of 26.5 kg/m2 and the second one utilised a population of children and adolescents with Prader-Willis Syndrome (PWS). Parameters assessing obesity, biochemical and appetite factors were analysed by carrying out a meta-analysis. Compared to placebo controlled group, C. fimbriata extract significantly reduced WC by 1.59 cm (95% CI, − 3.07 to − 0.10, p = 0.041) and WHR by 0.06 (95% CI, − 0.12 to − 0.01, p = 0.05) although no significant effects were seen on BW, BMI and HC. Biochemical and appetite parameters outcome on C. fimbriata consumption had no significant changes. Any side effects of individuals who ingested the extract were reported by few studies of which most common effects were constipation, diarrhoea, nausea and rashes. Conclusion Appetite parameters showed no significant changes and metabolic parameters did not improve with C.fimbriata supplementation therefore it is unlikely to recommend C. fimbriata as a weight loss supplement and an appetite suppressant.
format	article
author	Ranil Jayawardena Tormalli V. Francis Sachith Abhayaratna Priyanga Ranasinghe
author_facet	Ranil Jayawardena Tormalli V. Francis Sachith Abhayaratna Priyanga Ranasinghe
author_sort	Ranil Jayawardena
title	The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
title_short	The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
title_full	The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
title_fullStr	The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
title_full_unstemmed	The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
title_sort	use of caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials
publisher	BMC
publishDate	2021
url	https://doaj.org/article/8e4d0cbfd05b49ca95df52e90d17045f
work_keys_str_mv	AT raniljayawardena theuseofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT tormallivfrancis theuseofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT sachithabhayaratna theuseofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT priyangaranasinghe theuseofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT raniljayawardena useofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT tormallivfrancis useofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT sachithabhayaratna useofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials AT priyangaranasinghe useofcarallumafimbriataasanappetitesuppressantandweightlosssupplementasystematicreviewandmetaanalysisofclinicaltrials
_version_	1718429117967237120

The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials

Ejemplares similares